Study Evaluating Single Doses of ILV-095 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to evaluate the safety and tolerability of single doses of ILV-095 in healthy subjects.

Key facts

Study ID

NCT00822835

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

48

Starts

2009-01-01

Expected to finish

2009-08-01

Last updated by the study team

2009-09-18

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and women of non-childbearing potential ages 18 to 50 years old.
• Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight greater than or equal to50 kg.
• Healthy as determined by the investigator on the basis of screening evaluations.
• Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.
• Have a high probability for compliance with and completion of the study.

You may not qualify if…

• Presence or history of any disorder that may prevent the successful completion of the study.
• Any subject who had orthopedic surgery within 12 weeks of the screening visit or has planned (elective) orthopedic surgery within 12 weeks of study drug administration.
• Acute disease state (eg, nausea, vomiting, fever, active infection, or diarrhea) within 7 days before enrollment.

Where it is running

• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.